Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma

  View more

Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma

 View more

Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma

 View more

Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent, or metastatic cervical cancer: a multicenter, single arm, prospective phase II trial

 View more

Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

 View more

Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC

 View more

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study

 View more

Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

 View more

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma

 View more

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

 View more

Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer

 View more

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial

 View more

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

 View more